Research Analysts Set Expectations for AURA Q1 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright issued their Q1 2025 earnings per share estimates for Aura Biosciences in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.44) for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($2.11) EPS.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09).

Separately, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Down 0.8 %

NASDAQ:AURA opened at $5.94 on Thursday. The stock has a market capitalization of $296.71 million, a price-to-earnings ratio of -3.43 and a beta of 0.30. Aura Biosciences has a 52 week low of $5.77 and a 52 week high of $12.38. The firm has a 50 day moving average of $7.57 and a 200 day moving average of $8.62.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after buying an additional 3,612 shares during the last quarter. Geode Capital Management LLC lifted its stake in Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after acquiring an additional 3,972 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Aura Biosciences by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock valued at $227,000 after acquiring an additional 5,930 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Aura Biosciences in the fourth quarter worth $50,000. Finally, Bank of America Corp DE raised its holdings in shares of Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after purchasing an additional 8,709 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 23,045 shares of company stock worth $177,242 in the last three months. Corporate insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.